1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. VEGFR Agonist

VEGFR Agonist

VEGFR Agonists (7):

Cat. No. Product Name Effect Purity
  • HY-N0545
    Taurocholic acid sodium
    Agonist 98.14%
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
  • HY-P3325
    P8RI
    Agonist 99.49%
    P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.
  • HY-P5558
    KLTWQELYQLKYKGI
    Agonist 99.89%
    KLTWQELYQLKYKGI is a VEGF mimetic peptide designed based on the VEGF helix sequence 17-25, with the ability to activate VEGF receptors and exert pro-angiogenic biological activity. KLTWQELYQLKYKGI effectively promotes the attachment, spreading and proliferation of human umbilical vein endothelial cells. KLTWQELYQLKYKGI enhances the proliferation, migration and osteogenic differentiation of bone marrow stromal cells (BMSCs). KLTWQELYQLKYKGI synergistically accelerates angiogenesis and bone regeneration in rat cranial defect models. KLTWQELYQLKYKGI can be used for the research of brain tissue engineering and traumatic brain injury repair and biomaterials for bone tissue engineering and bone repair.
  • HY-N0545R
    Taurocholic acid sodium (Standard)
    Agonist
    Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
  • HY-W653842
    Taurocholic acid-d8 sodium
    Agonist 98.83%
    Taurocholic acid-d8 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
  • HY-N0545S
    Taurocholic acid-13C2,15N sodium
    Agonist
    Taurocholic acid-13C2,15N (sodium) is the 13C- and 15N- labeled Taurocholic acid (sodium).
  • HY-W653893
    Taurocholic acid-d5 sodium
    Agonist
    Taurocholic acid-d5 (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.